Compare GLP & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLP | TSHA |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2005 | 2020 |
| Metric | GLP | TSHA |
|---|---|---|
| Price | $42.70 | $5.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $45.00 | $10.22 |
| AVG Volume (30 Days) | 41.0K | ★ 3.8M |
| Earning Date | 11-07-2025 | 11-04-2025 |
| Dividend Yield | ★ 7.16% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.08 | N/A |
| Revenue | ★ $18,099,776,000.00 | $6,310,000.00 |
| Revenue This Year | $22.70 | N/A |
| Revenue Next Year | $42.12 | N/A |
| P/E Ratio | $20.28 | ★ N/A |
| Revenue Growth | ★ 4.10 | N/A |
| 52 Week Low | $39.70 | $1.05 |
| 52 Week High | $60.00 | $5.95 |
| Indicator | GLP | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 40.13 | 59.06 |
| Support Level | $41.76 | $5.22 |
| Resistance Level | $46.00 | $5.95 |
| Average True Range (ATR) | 1.65 | 0.34 |
| MACD | -0.14 | 0.05 |
| Stochastic Oscillator | 9.91 | 75.26 |
Global Partners LP is a limited partnership that acts as a midstream logistics and marketing company. It is mainly engaged in purchasing, selling, storing and logistics of transporting petroleum and related products. The company owns and operates and control terminal networks of refined petroleum products and renewable fuels in Massachusetts, Maine, Connecticut, Vermont, and other places. It distributes gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, natural gas and propane to wholesalers, retailers and commercial customers. The company operates through three segments i.e. Wholesale, Gasoline Distribution and Station Operations and Commercial. It generates maximum revenue from the Wholesale segment.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.